Loading clinical trials...
Loading clinical trials...
A Phase I, Multicenter, Open-Label, Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 Administered by Intravitreal Injection as Monotherapy and in Combination With Faricimab in Patients With Diabetic Macular Edema
Conditions
Interventions
RO7823653
Faricimab
Locations
8
United States
Associated Retina Consultants - Peoria - DocTrials - PPDS
Peoria, Arizona, United States
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
Retina Vitreous Associates of Florida
St. Petersburg, Florida, United States
Erie Retina Research, LLC - 300 State St
Erie, Pennsylvania, United States
Retina Research Institute of Texas
Abilene, Texas, United States
Austin Clinical Research, LLC
Austin, Texas, United States
Start Date
April 21, 2026
Primary Completion Date
November 17, 2028
Completion Date
November 17, 2028
Last Updated
April 23, 2026
NCT07308639
NCT07449936
NCT07449923
NCT06439576
NCT07228559
NCT05802329
Reference Study ID Number GR46431 https://forpatients.roche.com/
CONTACT
888-662-6728 (U.S. and Canada)global-roche-genentech-trials@gene.comLead Sponsor
Genentech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions